$TECH · BIO-TECHNE Corp
Bio-Techne held a Special Meeting on September 23, 2026, where shareholders voted to approve the Merger Agreement with Merck KGaA, Darmstadt, Germany. The deal, announced June 25, 2026, will see Merger Sub merge into Bio-Techne, with Bio-Techne surviving as a wholly-owned Merck KGaA subsidiary. The HSR waiting period expired September 18, 2026, and closing is expected by late 2026 or early 2027, subject to remaining regulatory approvals.
- 78.55% of outstanding shares were represented at the Special Meeting, constituting a quorum.
- The Merger Agreement Proposal passed with sufficient votes; the Adjournment Proposal was not submitted.
- HSR waiting period expired on September 18, 2026, clearing one regulatory hurdle.
- The Merger Agreement, dated June 25, 2026, provides for Merger Sub to merge into Bio-Techne, which survives as a Merck KGaA subsidiary.
- Bio-Techne generated over $1.2 billion in net sales in fiscal year 2025.
TECH shares are essentially flat (-0.04%) at $72.52 in the regular session. The shareholder vote was widely expected and the HSR clearance was already known, so the filing confirms deal progress without surprising the market.
Shareholder approval and HSR clearance remove two major contingencies for the Merck KGaA acquisition of the $1.2B-revenue life sciences tools provider.
The life sciences tools sector continues to consolidate, with Merck KGaA's acquisition of Bio-Techne following a pattern of large strategics acquiring reagent and diagnostics platforms to broaden workflow coverage from discovery through commercial manufacturing.
Closing remains subject to remaining regulatory approvals and customary conditions; failure to obtain them could delay or derail the transaction. Integration risk and potential business disruption during the pendency period are also flagged.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.